The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease

Rodziewicz, Mia; Kiely, Patrick

doi:10.1093/rheumatology/key146

Cited by 5 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abatacept has demonstrated notable effectiveness in reducing disease activity, marking a positive outcome in the treatment of muscular manifestations of DM [ 12 ]. Mia Rodziewicz’s work has shed light on the sustained therapeutic efficacy of abatacept in managing cutaneous and esophageal manifestations of anti-TIF1-γ-positive DM [ 13 ]. Following these recommendations, we employed corticosteroids, abatacept, methotrexate, and leflunomide in our approach.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis

Wu,

Chen,

Chen

et al. 2023

Medicina

View full text Add to dashboard Cite

An increase in skin-related autoimmune disorders has been reported as an adverse effect of coronavirus disease 2019 (COVID-19) vaccines. We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased. These findings suggest that standard DM treatment might be beneficial to patients with COVID-19 vaccine-induced DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis

Wu,

Chen,

Chen

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“…On the one hand, CTLA-4 downregulates T-cell activation by competing with CD28 to bind their common ligands CD80 and CD86, which results in the marked blocking activity of several key transcription factors, including AP-1(34 (13)(14)(15)(16). In addition, a retrospective study suggested that calcineurin inhibitors appear to be a good therapeutic option for managing ILD associated with ASS for refractory cases and as first-line treatment (50), suggesting a role for T-cell activation in ASS-ILD.…”

Section: Discussionmentioning

confidence: 99%

“…A randomised pilot trial assessing the effect of ABA in treating antisynthetase autoantibody-positive patients is underway, but no results have been published yet. Single case reports and a phase IIb clinical trial also indicate that ABA affects disease activity in patients with IIM (13)(14)(15)(16)(17). We retrospectively analysed clinical data from our centre to further explore the potential role of ABA in ASS-ILD.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series

Xia,

Hong,

Zhang

et al. 2022

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

ObjectiveThis study investigated the efficacy and safety of abatacept (ABA) in interstitial lung disease (ILD) associated with antisynthetase syndrome (ASS). Methods Eight patients were identified through retrospective analysis of the medical records of our centre. All patients fulfilled the Solomon criteria and had a disease complicated with ILD. Lung function, imaging, serum markers, clinical evaluation indicators of ILD, peripheral blood cell classification, cytokines, and prednisone doses were analysed. Results Seven of the eight patients were female. The mean age was 54.4 (standard deviation [SD] 6.0) years. Antibodies against Jo-1, PL-12, and PL-7 were present in three, three, and two patients respectively. At baseline, the mean diffusing lung capacity for carbon monoxide (DLCO) was 53.8% (SD 9.2%), the mean score of King's Brief Interstitial Lung Disease (KBILD) was 40.6 (SD 13.8), the median Krebs Von den Lungen-6 (KL-6) was 1612.5 (interquartile range [IQR] 1180.5-2431.5) U/ml. All patients experienced symptom alleviation after ABA therapy. The mean and median changes in DLCO percentage, KBILD, and KL-6 were 12.3% (p<0.05), 21.4 (p<0.01), and 174.5U/ml (p<0.01), respectively.No obvious adverse events related to ABA were observed during the treatment. ConclusionOur study offers preliminary, but encouraging, clinical evidence in favour of ABA as a therapy for ASS-ILD. ABA demonstrated favourable effects on ILD and was well-tolerated. Well-designed randomised controlled studies are required to confirm the efficacy and safety of this strategy.

show abstract

“…Combination of GC and immunosuppressants is chosen with the objective of [3], especially utilized as therapy for dysphagia (evidence level: V, recommendation grade: C1) [3,30]. Biological agents are used in cases of relapse of DM, such as Tocilizumab [31] (interleukin 6 receptor antagonist, recommendation grade: C1) [3], abatacept (fully human fusion of cytotoxic T lymphocyte antigen-4 and the Fc portion of immunoglobulin, recommendation grade: C1) [3,32] and rituximab (B-cell depleting agent, no recommendation grade) [21,33]. Plasmapheresis has been used in DM therapy (recommendation grade: C2) with unconvincing results [3].…”

Section: Medical Managementmentioning

confidence: 99%

Dermatomyositis: what the oral healthcare provider must know

Patil

Patil²

2020

J Oral Med Oral Surg

View full text Add to dashboard Cite

Dermatomyositis (DM) is an autoimmune condition characterized by skin rashes and progressive muscle weakness. It is classified under the idiopathic inflammatory myopathies (IIM) and can affect children as well as adults. A heightened incidence of malignancy in adults with DM has laid greater focus on its early diagnosis, treatment, and monitoring. In recent years, a greater understanding of the pathogenesis of the disease, its diagnostic criteria and management has improved the quality of life in affected individuals. The orofacial region presents with many manifestations of the disorder, sometimes even the initial presenting signs. This review presents an update on the disease process, its pathogenesis, diagnostic criteria, orofacial manifestations, medical management and dental considerations for patients with DM. The updated knowledge about DM is crucial for oral health care providers to plan and execute oral health care in a coordinated manner.

show abstract

The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease

Cited by 5 publications

References 7 publications

Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis

Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis

Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series

Dermatomyositis: what the oral healthcare provider must know

Contact Info

Product

Resources

About